title: Combination chemotherapy (CYVADIC) in metastatic soft tissue sarcomas.
abstract: Forty-one patients with metastatic sarcoma were treated with Adriamycin, 50 mg/m2 i.v. on day 1, Cyclophosphamide, 500 mg/m2 i.v. on day 1, Vincristine, 1 mg/m2 i.v. on days 1 and 5, and Dacarbazine (DTIC), 250 mg/m2 i.v. on days 1-5 (CYVADIC). Three patients had a complete regression, while 8 patients had a partial regression of greater than 50%. The combined response rate was 27%. Eight additional patients showed stabilization of disease for an average of 5 months while 22 patients progressed on CYVADIC. Ultimately, 7 patients with initial tumor regression had progression of their disease. Four patients with partial regression had excision of the regressed nodules of tumor and continued on chemotherapy for a year. They remain alive at a median follow-up of 24.5 months, suggesting that removal of partially regressed nodules may improve results.
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001853:Bone Marrow / Q000187:drug effects; D003520:Cyclophosphamide / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012509:Sarcoma / Q000188:drug therapy* / Q000556:secondary; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000556:secondary; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D014750:Vincristine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide